the very appearance of their names on such a website would imply wrongdoing, as if they were inherently compromised by any collaboration with industry. That risk is real enough. Any website should thus make it very clear that industry-academic collaboration is a valuable, indeed an essential, driver of biomedical innovation; that the translation of basic research to the clinic depends on it; and that it is encouraged both by US law -specifically, the Bayh-Dole Act of 1980 -and by the NIH.
That said, the ubiquitous interconnections between industry and academia -and the very desirability of a permeable boundary between the two -are probably the most compelling argument for the Sunshine Act. The transparency it would provide is a long overdue corrective to a culture that has too often seemed to look the other way when it comes to potential conflicts of interest. Such transparency would both shore up public trust and prompt researchers to tougher self-scrutiny as they complete their disclosures.
It's important to note that Grassley's Sunshine Act does not apply to non-physician scientists; he drafted it with medication-prescribing doctors in mind. Yet PhD scientists, too, play a vital part in many industry collaborations. For the sake of fairness and consistency, the act should apply to them as well.
Whether or not the Sunshine Act becomes law, the NIH is moving on a parallel track to tighten its own reporting rules for extramural researchers. A lowering of its $10,000 threshold for reporting is expected before the end of the year, for example. The agency should bear another principle in mind as it finalizes such changes: clarity in what is and is not reportable, with rules spelled out unambiguously. Increased clarity would protect NIH-funded researchers and the public they serve.
■

Taking the NICE path
The United States can learn from the UK body that rates the effectiveness of medical procedures. I n the highly polarized debate over US health-care reform, opponents of increased government involvement in the system frequently caricature Britain's National Health Service (NHS) as the disaster they want to avoid -an impenetrable snarl of red tape that keeps ailing pensioners on years-long waiting lists for even the most essential procedures. And at the heart of their nightmare is the UK National Institute for Health and Clinical Excellence (NICE), portrayed as a bunch of callous government bureaucrats ruling life-saving medications as off-limits to dying patients.
Globally, however, NICE is widely regarded as a world leader in comparative-effectiveness studies: research that aims to show which of the available medical options is most effective at treating any given condition, and which is worth the money -what US reform opponents might call 'health-care rationing' . Faced with an overwhelming yet incomplete medical literature, most medical professionals welcome NICE's best-practice guidelines on everything from early testing for breast cancer to child nutrition.
NICE's politically and emotionally fraught function can arouse intense feelings. In one example last year (see page 336), NICE had to make a Solomonic choice: should the NHS spend an extra £31,000 
